| Dr Lawrence E Speir Jr, DC | |
|
7 N 5th St, Albion, IL 62806-1021 | |
| (618) 445-3455 | |
| (618) 445-3411 |
| Full Name | Dr Lawrence E Speir Jr |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 21 Years |
| Location | 7 N 5th St, Albion, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932279460 | NPI | - | NPPES |
| 694802 | Other | IL | HEALTHLINK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 038-010124 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wabash General Hospital 1 | Mount carmel, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wabash General Hospital District | 8022908185 | 46 |
News Archive
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
In recent years, pharmaceutical companies in the Asia-Pacific region have ramped up their clinical trial activity, patent challenges of brand name drugs and their development of new products, according to report released Tuesday by CMR International, a Thomson Reuters business, Reuters reports.
The latest in a series of contaminated food scares from North America concerns a suspected outbreak of Escherichia coli (E. coli) which has left one person dead and seen many more admitted to hospital after eating at a restaurant in Locust Grove, Oklahoma.
SpectraScience, Inc. has announced that it has been awarded a patent for correcting image misalignment between at least two images in a sequence of images due at least in part to tissue sample movement. The patent, U.S. Patent No. 7,406,215, is titled "Methods and systems for correcting image misalignment."
Almac, in association with the Royal Society of Chemistry, hosted a scientific workshop focusing on advanced analytical techniques used to optimise, monitor and control solid state properties during the development of new medicines.
› Verified 5 days ago
| Provider Name | Wabash General Hospital District |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1295834208 PECOS PAC ID: 8022908185 Enrollment ID: O20040319001265 |
News Archive
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
In recent years, pharmaceutical companies in the Asia-Pacific region have ramped up their clinical trial activity, patent challenges of brand name drugs and their development of new products, according to report released Tuesday by CMR International, a Thomson Reuters business, Reuters reports.
The latest in a series of contaminated food scares from North America concerns a suspected outbreak of Escherichia coli (E. coli) which has left one person dead and seen many more admitted to hospital after eating at a restaurant in Locust Grove, Oklahoma.
SpectraScience, Inc. has announced that it has been awarded a patent for correcting image misalignment between at least two images in a sequence of images due at least in part to tissue sample movement. The patent, U.S. Patent No. 7,406,215, is titled "Methods and systems for correcting image misalignment."
Almac, in association with the Royal Society of Chemistry, hosted a scientific workshop focusing on advanced analytical techniques used to optimise, monitor and control solid state properties during the development of new medicines.
› Verified 5 days ago
| Provider Name | Speir Chiropractic, P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1962572313 PECOS PAC ID: 1850323742 Enrollment ID: O20050831000156 |
News Archive
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
In recent years, pharmaceutical companies in the Asia-Pacific region have ramped up their clinical trial activity, patent challenges of brand name drugs and their development of new products, according to report released Tuesday by CMR International, a Thomson Reuters business, Reuters reports.
The latest in a series of contaminated food scares from North America concerns a suspected outbreak of Escherichia coli (E. coli) which has left one person dead and seen many more admitted to hospital after eating at a restaurant in Locust Grove, Oklahoma.
SpectraScience, Inc. has announced that it has been awarded a patent for correcting image misalignment between at least two images in a sequence of images due at least in part to tissue sample movement. The patent, U.S. Patent No. 7,406,215, is titled "Methods and systems for correcting image misalignment."
Almac, in association with the Royal Society of Chemistry, hosted a scientific workshop focusing on advanced analytical techniques used to optimise, monitor and control solid state properties during the development of new medicines.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lawrence E Speir Jr, DC 7 N 5th St, Albion, IL 62806-1021 Ph: (618) 445-3455 | Dr Lawrence E Speir Jr, DC 7 N 5th St, Albion, IL 62806-1021 Ph: (618) 445-3455 |
News Archive
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
In recent years, pharmaceutical companies in the Asia-Pacific region have ramped up their clinical trial activity, patent challenges of brand name drugs and their development of new products, according to report released Tuesday by CMR International, a Thomson Reuters business, Reuters reports.
The latest in a series of contaminated food scares from North America concerns a suspected outbreak of Escherichia coli (E. coli) which has left one person dead and seen many more admitted to hospital after eating at a restaurant in Locust Grove, Oklahoma.
SpectraScience, Inc. has announced that it has been awarded a patent for correcting image misalignment between at least two images in a sequence of images due at least in part to tissue sample movement. The patent, U.S. Patent No. 7,406,215, is titled "Methods and systems for correcting image misalignment."
Almac, in association with the Royal Society of Chemistry, hosted a scientific workshop focusing on advanced analytical techniques used to optimise, monitor and control solid state properties during the development of new medicines.
› Verified 5 days ago
Dr. Gary R Stevens, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 21 W Main St, Albion, IL 62806 Phone: 618-445-2419 | |
Speir Chiropractic, P.c. Chiropractor Medicare: Medicare Enrolled Practice Location: 7 N 5th St, Albion, IL 62806 Phone: 618-445-3455 Fax: 618-445-3411 |